https://hstalks.com/therapeutic-area/8/oncology/?biosci New and updated series & talks on Oncology from HSTalks' Biomedical & Life Sciences Collection. daily 1 2006-01-01T12:00+00:00 Henry Stewart Talks en © Copyright Henry Stewart Talks Ltd. The Biomedical & Life Sciences Collection © Copyright Henry Stewart Talks Ltd. https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci Ongoing clinical trials for bladder cancer - Enfortumab-vedotin & pembrolizumab as first-line therapy - Disitamab vedotin & toripalimab (PD1 inhibitor) for the treatment of metastatic UC - Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions - Remission with cisplatin-based NAC - mRNA-4157 (V940): customizable individualized mRNA immunotherapy - Adjuvant chemotherapy - Neoadjuvant Chemo-IO combination therapy Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials Prof. Guru P. Sonpavde Ongoing clinical trials for bladder cancer, Enfortumab-vedotin & pembrolizumab as first-line therapy, Disitamab vedotin & toripalimab (PD1 inhibitor) for the treatment of metastatic UC, Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions, Remission with cisplatin-based NAC, mRNA-4157 (V940): customizable individualized mRNA immunotherapy, Adjuvant chemotherapy, Neoadjuvant Chemo-IO combination therapy 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci Bladder cancer: incidence and epidemiology - Bladder cancer risk factors - Lynch syndrome - Bladder cancer: pathology, staging and diagnosis - Initial therapy for NMIBC (non-muscle-invasive bladder cancer) Bladder cancer: types, risk factors, diagnosis, treatment and prevention: introduction to bladder cancer Prof. Guru P. Sonpavde Bladder cancer: incidence and epidemiology, Bladder cancer risk factors, Lynch syndrome, Bladder cancer: pathology, staging and diagnosis, Initial therapy for NMIBC (non-muscle-invasive bladder cancer) 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/21178/surgical-treatment-of-lymphedema-current-approache/?biosci The train station analogy - Lymph node transplant - Lymphovenous bypass - Excisional procedure - Axillary reverse mapping (ARM) - Lymphatic microsurgical preventive healing approach (LYMPHA) - Immediate lymphatic reconstruction - Predisposition to lymphedema - Mascagni Sappey pathway - Axillary and cephalic pathways - Long vs. short bundle - Mapping the lymphatic system Surgical treatment of lymphedema: current approaches & future directions Dr. Dhruv Singhal The train station analogy, Lymph node transplant, Lymphovenous bypass, Excisional procedure, Axillary reverse mapping (ARM), Lymphatic microsurgical preventive healing approach (LYMPHA), Immediate lymphatic reconstruction, Predisposition to lymphedema, Mascagni Sappey pathway, Axillary and cephalic pathways, Long vs. short bundle, Mapping the lymphatic system 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci Cancer vaccines - Cancer immunotherapy - Ovarian cancer - Tumour antigens - Whole-cell vaccines - T-cell activation - Tumour microenvironment - Clinical development of immunotherapies Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy Prof. Raymond Goodrich Cancer vaccines, Cancer immunotherapy, Ovarian cancer, Tumour antigens, Whole-cell vaccines, T-cell activation, Tumour microenvironment, Clinical development of immunotherapies 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/24940/unlocking-a-new-class-of-cancer-targets-neoantigen/?biosci Public neoantigens - Alternative splicing-derived neojunctions - Cancer immunotherapy - Brain tumours (gliomas) - T-cell receptor (TCR)-based therapy - Cancer vaccines - Intratumour heterogeneity - Tumour-specific antigens - Human leukocyte antigen (HLA) presentation - Off-the-shelf immunotherapies Unlocking a new class of cancer targets: neoantigens from RNA splicing Dr. Hideho Okada Public neoantigens, Alternative splicing-derived neojunctions, Cancer immunotherapy, Brain tumours (gliomas), T-cell receptor (TCR)-based therapy, Cancer vaccines, Intratumour heterogeneity, Tumour-specific antigens, Human leukocyte antigen (HLA) presentation, Off-the-shelf immunotherapies 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection